Bolt Biotherapeutics (NASDAQ:BOLT) and Lipella Pharmaceuticals (NASDAQ:LIPO) Head-To-Head Review

Lipella Pharmaceuticals (NASDAQ:LIPO) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends.

Analyst Ratings

This is a summary of current recommendations for Lipella Pharmaceuticals and Bolt Biotherapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipella Pharmaceuticals	0	0	0	0	0.00
Bolt Biotherapeutics	1	1	2	0	2.25

Bolt Biotherapeutics has a consensus price target of $14.50, suggesting a potential upside of 264.32%. Given Bolt Biotherapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Bolt Biotherapeutics is more favorable than Lipella Pharmaceuticals.

Volatility & Risk

Lipella Pharmaceuticals has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, Bolt Biotherapeutics has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.

Profitability

This table compares Lipella Pharmaceuticals and Bolt Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lipella Pharmaceuticals	-988.83%	-224.08%	-172.88%
Bolt Biotherapeutics	-611.47%	-126.23%	-54.70%

Insider & Institutional Ownership

74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by company insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Lipella Pharmaceuticals and Bolt Biotherapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipella Pharmaceuticals	$536,357.00	0.28	-$5.02 million	($2.42)	-0.01
Bolt Biotherapeutics	$7.70 million	1.00	-$33.38 million	($16.44)	-0.24

Lipella Pharmaceuticals has higher earnings, but lower revenue than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Lipella Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Bolt Biotherapeutics beats Lipella Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

About Lipella Pharmaceuticals

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.